Trump has begun another trade war. Here's a timeline of how we got here
Canada's leader laments lost friendship with US in town that sheltered stranded Americans after 9/11
Chinese EV giant BYD's fourth-quarter profit leaps 73%
You're an American in another land? Prepare to talk about the why and how of Trump 2.0
Chalk talk: Star power, top teams and No. 5 seeds headline the women's March Madness Sweet 16
Purdue returns to Sweet 16 with 76-62 win over McNeese in March Madness
(Reuters) - KKR has abandoned a private equity consortium discussing a takeover of Gerresheimer AG, Bloomberg News reported on Thursday, citing people familiar with the matter.
Warburg Pincus, which was also a part of the consortium, is still working to see if it can reach a deal, the report said.
Earlier this month, Reuters reported that a consortium including KKR and Warburg Pincus had submitted a non-binding bid for Gerresheimer.
Gerresheimer, which makes pens used to inject weight-loss drugs such as Novo Nordisk's Wegovy, has a market capitalization of about 2.22 billion euros, according to LSEG data.
The consortium had submitted a bid at about 90 euros a share, which would value the company at nearly 3.1 billion euros ($3.42 billion).
Gerresheimer and Warburg Pincus declined to comment while KKR did not immediately respond to Reuters' requests for comment.
In February, the German company said it was in early-stage discussions with private equity investors over a potential sale of the company.
Gerresheimer said at that time that the interest was informal and on a non-binding basis.
($1 = 0.9065 euros)
(Reporting by Pretish M J in Bengaluru; Editing by Alan Barona and Maju Samuel)
